Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability